IP Library › Granted Patent US 12,329,727
Granted Patent B2
US 12,329,727 · App. 17/920,611 · Granted Jun 17, 2025

Use of salmeterol as an anti-coronaviral agent

Inventors: Jonathan Stephen Marchant (Brookfield, WI); Tom Paul Aufderheide (Wauwatosa, WI)
Assignee: The Medical College of Wisconsin, Inc.
A61K31/137A61K45/06A61P31/14
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,329,727
App. No.
17/920,611
Granted
Jun 17, 2025
Kind
B2
Abstract

Described herein are methods for treating COVID-19 or preventing COVID-19 in a subject exposed to SARS-CoV-2 by administering to the subject a therapeutically effective amount of salmeterol or the pharmaceutically acceptable salt thereof.

Claims (18)

1. A method for treating coronavirus disease 2019 (COVID-19) in a subject in need thereof comprising administering to the subject a composition comprising a therapeutically effective amount of salmeterol or a pharmaceutically acceptable salt thereof, whereby one or more symptoms of COVID-19 are improved in the subject and wherein the composition is administered by inhalation.

2. The method of claim 1 , wherein the pharmaceutically acceptable salt is salmeterol xinafoate.

3. The method of claim 1 , wherein the composition comprises a propellant.

4. The method of claim 1 , wherein the composition is administered to the nasal mucosal tissue of the subject.

5. The method of claim 4 , wherein the composition is administered to the subject as a nasal spray.

6. The method of claim 1 , wherein the composition is a suspension of powdered salmeterol or the pharmaceutically acceptable salt thereof.

7. The method of claim 1 , wherein the composition additionally comprises a steroid.

8. The methods of claim 1 , wherein salmeterol or the pharmaceutically acceptable salt thereof is administered in a single or multiple doses of 10 μg to 100 μg per dose.

9. A method of reducing the severity of COVID-19 in a subject exposed to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) comprising administering to a subject exposed to SARS-CoV-2 a composition comprising a therapeutically effective amount of salmeterol or a pharmaceutically acceptable salt thereof, whereby one or more symptoms of COVID-19 is treated and wherein the composition is administered by inhalation.

10. The method of claim 9 , wherein the pharmaceutically acceptable salt is salmeterol xinafoate.

11. The method of claim 9 , wherein the composition comprises a propellant.

12. The method of claim 9 , wherein the composition is administered to the nasal mucosal tissue of the subject.

13. The method of claim 12 , wherein the composition is administered to the subject as a nasal spray.

14. The method of claim 9 , wherein the composition is a suspension of powdered salmeterol or the pharmaceutically acceptable salt thereof.

15. The method of claim 9 , wherein the composition additionally comprises a steroid.

16. The method of claim 9 , wherein salmeterol or the pharmaceutically acceptable salt thereof is administered in a single or multiple doses of 10 μg to 100 μg per dose.

17. A method of inhibiting SARS-CoV-2 infectivity in a mammalian cell comprising administering to the mammalian cell a composition comprising a therapeutically effective amount of salmeterol or a pharmaceutically acceptable salt thereof, wherein salmeterol or the pharmaceutically acceptable salt thereof inhibits nicotinic acid adenine dinucleotide phosphate (NAADP) mediated Ca 2+ release and uptake of SARS-CoV-2 by two-pore channel (TPC) receptors of the mammalian cell and wherein the composition is administered by inhalation.

18. The method of claim 17 , wherein the mammalian cell is a nasal mucosal cell of a human subject exposed to SARS-CoV-2.

Assignments (2)
CONFIRMATORY LICENSE Recorded Aug 2, 2023
From: MEDICAL COLLEGE OF WISCONSIN
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 064641/0773 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 22, 2022
From: MARCHANT, JONATHAN STEPHEN; AUFDERHEIDE, TOM PAUL
To: THE MEDICAL COLLEGE OF WISCONSIN, INC.
Reel/Frame 061504/0588 →
Continuity (2)
Provisional Application 63015307 · Apr 24, 2020
Related Publication 20230149327A1 · May 18, 2023
References Cited (27)
US 6303103B1 · Akehurst et al. · 2001 [cited by applicant]
US 7090831B1 · Bonvoisin et al. · 2006 [cited by applicant]
US 20040050960A1 · Godfrey et al. · 2004 [cited by applicant]
US 20050042174A1 · Nilsson et al. · 2005 [cited by applicant]
US 20130203715A1 · Hava et al. · 2013 [cited by applicant]
US 20170304564A1 · DeHaan et al. · 2017 [cited by applicant]
WO 2012107765A2 · 2012 [cited by applicant]
International Search Report issued for PCT/US2021/028399 dated Jul. 14, 2021. [cited by applicant]
International Preliminary Report on Patentability issued for PCT/US2021/028399 dated Jul. 14, 2021. [cited by applicant]
Britton, M. G., et al., “A twelve month comparison of salmeterol with salbutamol in asthmatic patients.” European Study Group. Eur. Respir. (1992) J. 5, 1062-1067. [cited by applicant]
D'Alonzo, G. E., et al., “Salmeterol xinafoate as maintenance therapy compared with albuterol in patients with asthma.” JAMA (1994) 271, 1412-1416. [cited by applicant]
Devalia, J. L., et al., “The effects of salmeterol and salbutamol on ciliary beat frequency of cultured human bronchial epithelial cells, in vitro.” Pulm. Pharmacol. (1992) 5, 257-263. [cited by applicant]
Gunaratne, G. S., et al., “Essential requirement for Jupiter Microtubule Associated Homolog 2 in NAADP-evoked Ca2+ signaling and SARS-COV-2 infectivity.” Science Signaling (in press) (2021) vol. 14; Issue 675; DOI: 10.1… [cited by applicant]
Gunaratne, G. S., et al., “NAADP-dependent Ca(2+) signaling regulates Middle East respiratory syndrome-coronavirus pseudovirus translocation through the endolysosomal system.” Cell Calcium (2018) 75, 30-41. [cited by applicant]
Gunaratne, G. S., et al., “A screening campaign in sea urchin egg homogenate as a platform for discovering modulators of NAADP-dependent Ca(2+) signaling in human cells.” Cell Calcium (2018) 75, 42-52. [cited by applicant]
Li, X., et al., “An antiinflammatory effect of salmeterol, a long-acting beta(2) agonist, assessed in airway biopsies and bronchoalveolar lavage in asthma.” Am. J. Respir. Crit. Care Med. (1999) 160, 1493-1499. [cited by applicant]
https://www.cdc.gov/coronavirus/2019-ncov/your-health/treatments-for-severe-illness.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fcoronavirus%2F2019-ncov%2Fhcp%2Ftherapeutic-options.html. [cited by applicant]
Liu et al. “Research and development on therapeutic agents and vaccines for COVID-19 and related human coronavirus diseases,” ACS Central Science (2020) 6, 315-331. [cited by applicant]
Maris, N. A., et al., “Antiinflammatory effects of salmeterol after inhalation of lipopolysaccharide by healthy volunteers.” Am. J. Respir. Crit. Care Med. (2005) 172, 878-884. [cited by applicant]
Nelson, H. S., “Advair: combination treatment with fluticasone propionate/salmeterol in the treatment of asthma.” J. Allergy Clin. Immunol. (2001) 107, 398-416. [cited by applicant]
Ou, X., et al., “Characterization of spike glycoprotein of SARS-COV-2 on virus entry and its immune cross-reactivity with SARS-COV.” Nature Communications (2020) 11, 1620. [cited by applicant]
Penny, C. J., et al., “Mining of Ebola virus entry inhibitors identifies approved drugs as two-pore channel pore blockers.” Biochim Biophys Acta Mol Cell Res (2019) 1866, 1151-1161. [cited by applicant]
Pearlman, D. S., et al., “A comparison of salmeterol with albuterol in the treatment of mild-to-moderate asthma.” N. Engl. J. Med. (1992) 327, 1420-1425. [cited by applicant]
Sakurai, et al., “Ebola virus. Two-pore channels control Ebola virus host cell entry and are drug targets for disease treatment.” Science (2015) 347, 995-998. [cited by applicant]
Shang, J., et al., “Cell entry mechanisms of SARS-COV-2.” Proc. Natl. Acad. Sci. U. S. A. (2020) 117, 11727-11734. [cited by applicant]
Taylor, D. R., et al., “Asthma control during long-term treatment with regular inhaled salbutamol and salmeterol.” Thorax (1998) 53, 744-752. [cited by applicant]
Trott, O., et al., “AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading.” Journal of computational chemistry (2010) 31, 455-461. [cited by applicant]